Prosecution Insights
Last updated: November 04, 2026

Rev Genomics Inc.

Technology area: Biotechnology & Pharmaceuticals

3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready

Analysis

Rev Genomics Inc. has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are handled by 3 distinct examiners. All prosecution activity is concentrated within a distinct art unit. The company's current patent applications are being reviewed by multiple examiners despite being limited to a particular technical group.

DEQUANTARIUS JAVON SPEED is the busiest examiner, currently managing 1 pending action. This matches the workload of the other distinct examiners. The concentration of 3 pending actions within a distinct art unit suggests a specific technical focus despite the involvement of multiple examiners. Practitioners should note that while the pending office actions are in a single art unit, they are being reviewed by different individuals. This arrangement means that the matters are reviewed by different examiners. The pending office actions in the Biotechnology & Pharmaceuticals area are each assigned to a distinct examiner. This distribution ensures that each of the actions receives an independent evaluation within the 1 art unit.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

3
Total Pending OAs
2
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)3 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SPEED, DEQUANTARIUS JAVON 1 70.0% +69.2%
WILLIAMS, KEITH RICHARD 1 44.4% +0.0%
STOCKDALE, JESSICA NICOLE 1 51.4% +33.3%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18811676 Self-Fertilization as Methods for Stabilizing Ploidy after Colchicine Treatment Model WILLIAMS, KEITH RICHARD 118d overdue
17860013 Submersion-Free Systems and Methods to Genetically Transform Cannabis Sativa STOCKDALE, JESSICA NICOLE 73d overdue
19225975 GIBBERELLIC ACID AND THE FORMATION OF MALE REPRODUCTIVE STRUCTURES ON FEMALE CANNABIS PLANTS SPEED, DEQUANTARIUS JAVON —

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
17860013 Submersion-Free Systems and Methods to Genetically Transform Cannabis Sativa STOCKDALE, JESSICA NICOLE 73d overdue
19225975 GIBBERELLIC ACID AND THE FORMATION OF MALE REPRODUCTIVE STRUCTURES ON FEMALE CANNABIS PLANTS SPEED, DEQUANTARIUS JAVON —

Top Art Units

Art UnitApps
1663 3

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19225975 GIBBERELLIC ACID AND THE FORMATION OF MALE REPRODUCTIVE STRUCTURES ON FEMALE CANNABIS PLANTS SPEED, DEQUANTARIUS JAVON 1663 §102§103§112 Non-Final OA — Pending Jun 02, 2025
18811676 Self-Fertilization as Methods for Stabilizing Ploidy after Colchicine Treatment Model WILLIAMS, KEITH RICHARD 1663 §102§103§112 Non-Final OA 118d overdue Pending Aug 21, 2024
17860013 Submersion-Free Systems and Methods to Genetically Transform Cannabis Sativa STOCKDALE, JESSICA NICOLE 1663 §103§112 Final Rejection 73d overdue Pending Jul 07, 2022

Managing Rev Genomics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Rev Genomics Inc. have?

Rev Genomics Inc. has 3 pending office actions as of November 2026, spread across 1 art units and 3 examiners.

Which USPTO examiner handles the most Rev Genomics Inc. applications?

Dequantarius Javon Speed has the most, with 1 of Rev Genomics Inc.'s pending office actions.

What technology area are Rev Genomics Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month